Method of treating subclinical mastitis in cows

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing the more effective mosquito puncture procedures for the purpose of treating subclinical mastitis in cows by the effect of mosquitoes on biologically active points. That is ensured by the fact that the exposure covers the biologically active points from both sides of a sacral bone by introducing 20 mosquitoes for 4-5 minutes. The procedures are performed four times every 24 hours.

EFFECT: method provides the clinical effectiveness of 93,3% and is less labour-consuming and environmentally safe as compared to the other methods.

 

The invention relates to agriculture, in particular for veterinary medicine, in particular to a method of treatment of subclinical mastitis in cows.

The fight against mastitis cows is one of the major problems of dairy cattle. According to the International dairy Association annual clinical form of mastitis perebolevayet 10-12% of cows, and subclinical up to 50%. Mastitis causes enormous economic damage. This is a reduction of milk production and premature culling valuable in breeding and productive animals, deterioration of the nutritional and technological properties of milk and culling, the cost of diagnosis and treatment.

Veterinary science and practice there has been significant progress in the treatment of mastitis in cows, but the disease continues to affect a large number of milch cows.

With the purpose of treatment of subclinical mastitis proposed a large number of tools and techniques, but they are ineffective, and the wide use of preparations containing antibiotics leads to antibiotic-resistant strains of microorganisms, and the penetration of antibiotics into the food people leads to allergic diseases. In this regard, the search for new effective methods of treatment of subclinical mastitis in cows that do not have negative side effects on animals and man the ESA, at the same time environmentally friendly is a very important task of veterinary science and practice.

Currently, for the treatment of mastitis in cows are frequently used methods based on ancient Chinese method of treatment of various human diseases using acupuncture (acupuncture - Tsyu therapy). These include: exposure to currents of low intensity (electro), laser beam (puncture), cold (biopuncture), burning, pressure, magnetic field, irritating drugs on biologically active points (BDT) on the body of the animal [1, S. 3].

The basis of acupuncture is the irritation of the numerous nerve endings of the skin, subcutaneous tissue, tendons, periosteum, blood vessels and finally the peripheral nerve endings. The pulses from the biologically active points on the centripetal nerves come in a variety of areas of the spinal cord and reach the highest parts of the Central nervous system, regulating and controlling the activities of all organs and systems.

Currently known methods of treatment of mastitis in cows with acupuncture.

Complex effect on the acupuncture points of the magnetic field, infrared and laser radiation. This uses the device of "WET-MIL". The selection of acupuncture points is performed using the device of VETTA-D". The hcpa shall setout on acupuncture points within 2 minutes. The number of procedures from 3 to 6. The effectiveness of treatment is 87-100%, depending on the nature of the inflammation of the udder [2, S. 224-225].

Treatment of mastitis with electrostimulation. To this end the device will be used "Elite 4M, (current L-shaped form, the pulse frequency 100-350 Hz, amplitude 3-7), impact on biologically active points Qi-Hai-Shu, Dan-Chung-Shu, Guan-yuan-Shu and Xiao-Chang-Shu (paired) through the steel acupuncture needles, previously entered in the Sacro-lumbar region along the Meridian of the bladder.

For determining BAT are cross-costal process of the second lumbar vertebra, and, departing from its outer edge 5 cm, spend a notional line parallel to the median, which points are: Qi-Hai-Shu - between the third and fourth, Yes-Chan-Shu - between the fourth and fifth, Guan-yuan-Shu between the fifth and sixth transverse costal processes of the respective lumbar vertebrae. The point of Xiao-Chang-Shu is at the intersection of the line with a perpendicular line running from the first sacral foramen.

Precise localization of the BAT is determined using a special probe, with indicator light. The duration of elektrorazpredelenie acupuncture points 20 minutes [4, S. 45-46 - prototype].

The purpose of the invention is to achieve high treatment efficiency camaroptera with klinicheskom mastitis in cows by the impact of mosquitoes on biologically active points, as a less labor-intensive and environmentally friendly way.

The proposed method of treatment of subclinical mastitis with mosquitoes on the principle of camaroptera has no side effects on animals, does not require acquisition costs of complex equipment and electricity.

In the experience on the principle of analogues were selected 12 cows with subclinical mastitis, which was affected 15 a share of the udder.

The diagnosis of subclinical mastitis in cows was established based on the positive reactions of milk with 2% solution of masticina. To avoid irritation of the udder study of milk was repeated over three days.

When confirming the diagnosis of subclinical mastitis in cows on both sides of the sacral bone was placed mosquitoes in cages, which is located within the approximate location of the BAT. After sucking mosquitoes to the skin Zadok was carefully removed. On each side of the sacral bone put 20 mosquitoes. After saturation of the blood (4-5 minutes) mosquitoes spontaneously flew away. The treatment was performed four times with an interval of 24 hours.

7 days after the end of treatment to determine therapeutic efficacy of cameracapture with subclinical mastitis in cows again explored the milk from experimental animals using a 2% solution of masticina.

The research results show the Lee, when using camaroptera for the treatment of subclinical mastitis in cows with 15 affected shares udder recovered 14 a share.

Thus, therapeutic efficacy of camaroptera with subclinical mastitis in cows amounted to 93.3%, which is considerably higher than when using chemotherapeutic drugs and physiotherapy treatments.

Sources of information

1. Kazeev, Century, Varlamov E. C., starchenkov A. C. application of the method of acupuncture for the prevention and treatment of obstetric-gynecological diseases and impotence bulls (recommendations). - Moscow. Center for scientific and technical information, promotion and advertising. 1974. 17 C.

2. Kazeev, B., starchenkov D. B. Therapy of mastitis by complex effects on the acupuncture points of the magnetic field, infrared and laser radiation. Materials of all-Russian scientific and educational-methodical conference on obstetrics, gynecology and bioengineering of animal reproduction. Voronezh, 1994. 224-225 C.

3. Nikonov G. I. Medical leech. Fundamentals of hirudotherapy. "SDS". Saint-Petersburg. 1998. 275 C.

4. Chuchin C. I., Mironov, K. N. Electroacupuncture with serous mastitis in cows // veterinary medicine, 1987, No. 6, 45-46 C.

The method of treatment of subclinical mastitis in cows by influence on biologically active points, characterized in that the impact of exercise on bi is logically active points, located on both sides of the sacral bone, by riding on 20 mosquitoes for 4-5 minutes four times with an interval of 24 hours



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day.

EFFECT: method provides the 100% clinical effectiveness in latent mastitis, being less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and concerns an immunostimulant composition containing a compound of formula I; to a method for enhancing the immune response to an antigen in an individual, involving administering the antigen and composition into the individual. Enhancing the immune response can represent enhancing the antibody-mediated immune response, CD4+ T-cell response, CD8+ T-cell response or activating the antigen-presenting cells. What is also presented is a method for enhancing the immune response by administering the antigen and composition containing the compound of formula I intramuscularly.

EFFECT: group of inventions enables achieving enhancing the immune response to the antigen.

24 cl, 7 ex, 13 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a pneumococcal vaccine containing saccharide of 4, 6B, 9V, 14, 18C, 19F and 23F serotypes, separately conjugated with CRM197, and at least one Toll-like receptor-9 (TLR-9) agonist as an adjuvant, wherein the above Toll-like receptor-9 agonist represents CpG-oligonucleotide. Also, the group of inventions concerns using the pneumococcal vaccine for preparing the therapeutic agent for preventing or treating diseases caused by S.pneumoniae; a method for individual's immunisation against the diseases caused by S.pneumoniae infection, involving administering the immunoprotective dose of the vaccine into the above individual.

EFFECT: adding B-class CpG to the conjugated pneumococcal vaccine provides the considerable increase of the proportion of highly responsive patients, good tolerance and cell memory induction in relation to pneumococcal polysaccharides.

45 cl, 9 dwg, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a group if inventions: a pharmaceutical composition, containing immunologically active enantiomer of a component of the cationic lipid R-DOTAP or S-DOTAP, a method of applying the said enantiomer for induction of an immunostimulating adjuvant effect in the immune system, a method of inducing immune response in a patient with applying thereof and a method of treatment or prevention of a disease in the patient by induction of the immunostimulating adjuvant effect by the lipid.

EFFECT: R-DOTAP and S-DOTAP induced production of cytokines IL-2, IL-8, IL-12, chemokines CCL-5, CCL-19 and tumour regression in mice.

23 cl, 15 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: abdominal paracentesis is performed to remove ascetic fluid to be concentrated and filtered by means of hemodialysis filter and plasma filter. The prepared concentrate is added with human recombinant interleukin-2 in a dose of 500 IU. The concentrate is refused intravenously at a perfusion rate of 60 drops a minute in an amount of 500 ml. On the day following the abdominal paracentesis, the concentrate is introduced again.

EFFECT: method provides effective elimination of hypo- and dysproteinemia in the given category of patients, as well as the correction of immune disorders by using plasma self-proteins and cytokines that enables the further surgical correction of the detected pathology.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to immunology, and can be used for obtaining medication for preventive treatment of tuberculosis. Immunotherapeutic medication contains fragments of cell wall of Mycobacterium tuberculosis complex (MTB-C).

EFFECT: claimed medication is obtained by method including the following stages: cultivation of virulent strain of MTB-C for the period, equal or longer than three weeks, and homogenisation of cell culture in presence of non-ionic surface-active substance.

14 cl, 2 ex, 2 tbl

FIELD: food industry.

SUBSTANCE: inventions group relates to food industry. The nutritive composition for improvement of the immune system with a mammal, preferably, with the human includes the following components: (a) at least 18 en% of protein material; (b) at least 12 wt % of leucine of the total quantity of protein material; (c) lipid fraction including at least one ω-3 polyunsaturated fatty acid chosen from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) immunomodulator.

EFFECT: inventions group ensures intensification of protective immune response to an exogenous pathogene or autologous trigger such as neoplastic cells as well as improved humoral immunity or their combination.

17 cl, 4 dwg, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, concerns a method for correction of secondary immunodeficiency in calves. A phytopreparation representing a 70% alcoholate of purple Echinacea (Echinacea purpurea L.) herb and blossom clusters, common pine (PHnus sylvestris) buds, yellow starwort (Inula helenium) roots and rhizomes, common licorice (Glycyrrhiza glabra L.) roots, common harmala (Peganum harmala) herb taken in the ratio 1:1:1:1:0.5 is administered orally in clinically healthy calves in the form of 7-8% aqueous solution in a dose of 2.0-2.5 ml/kg of an animal's body weight for 10-15 days every 24 hours.

EFFECT: invention provides correcting secondary immunodeficiency to physiological standard that enables preventing gastrointestinal and respiratory diseases in calves.

4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula (1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.

EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.

26 cl, 20 dwg, 8 tbl, 13 ex

FIELD: food industry.

SUBSTANCE: composition with hepato-protective and immunostimulating properties contains oxygenated dextran with molecular weight equal to 40-70 kDa and a vegetal raw material component chosen from the following group: dry Saint-Mary-thistle fruits extract, dry hill-growing saltwort extract, dry purple echinacea herb extract as well as microcrystalline cellulose as a physiologically acceptable filler, taken in a specified quantity.

EFFECT: hepato-protective and immunostimulating properties enhancement.

1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day.

EFFECT: method provides the 100% clinical effectiveness in latent mastitis, being less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary obstetrics and veterinary sanitary, and provides avoiding the use of expensive import preparations and preparations containing antibiotics. The preparation for treating mastitis in lactation cows contains dioxidin, and additionally contains xanthane gum, tetramethylene diethylene tetramine lactam, and methyluracil in the following proportions, wt %: dioxidin-1.0; xanthane gum - 0.18; tetramethylene diethylene tetramine lactam - 3.0; methyluracil - 0.5; distilled water - 95.32.

EFFECT: invention provides more effective and cheap treatment of the animals.

1 tbl

FIELD: medicine.

SUBSTANCE: invention is applicable in veterinary science for treating mastitis in animals. A tylosin agent for treating mastitis in animals additionally contains glycerol, Carbopol, triethanol amine, fir essence in the following proportions, %: tylosin 0.05-1.0; glycerol 5.0-10.0; Carbopol 0.15 -0.20; triethanol amine 0.02-0.03; fir essence 0.1-0.3; water up to 100. The agent shows a good wound healing effect, creates a thin surface film, soothes skin, possess antiseptic properties, ability to scare insects, flies in particular.

EFFECT: invention provides higher preventive effectiveness of the agent and lower cost price of animal treatment.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary medicine. A method of treating (therapy) subclinical mastitis in cows involves the introduction of the St. John's wort tea 15 ml in the involved lobes of mammary gland three times every 24 hours combined with the single intramuscular introduction of the stress corrector Ligfol 5 ml.

EFFECT: invention provides higher clinical effectiveness.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a set for hypogalactia prevention in women with thyroid diseases. The set for hypogalactia prevention in women with thyroid diseases which includes the preparations: aminophylline; no-spa; a preparation improving blood rheology specified in the group: rheopolyglucinum, fresh frozen plasma, a microdose of aspirin; an energy preparation specified in the group: glucose, actovegin; amino acid specified in the group: methionine, glutamic acid, galascorbinum; antioxidants, a ferriferous preparation specified in the group: Sorbifer Durules, tardiferon; and a vitamin complex containing vitamins A, E, C.

EFFECT: set reduces rate and severity of lactation disorders in women with a thyroid pathology and improves breast milk quality.

2 cl

FIELD: medicine.

SUBSTANCE: said preparation contains the components as follows, %: Lincomycin hydrochloride 2.0-4.0; Dioxidine 0.5-1.0; soft Monoglyceride 3.0; distilled Monoglyceride 3.0; Vaseline oil to 100. The preparation is applied to treat all forms of mastitis in lactating period. Prior to introduction thereof, udder secretion is milked dry from an affected portion and utilised; a dug is disinfected. Before use, the contents of a syrette or a bottle is heated up to 37°C, agitated thoroughly to a uniform suspension, a sterile syringe is filled with 10 ml thereof from the bottle. The syringe or the syrette is tightly pressed to outer orifice of teat canal. The preparation is introduced therein by careful pressing the syringe piston. After introduction, gentle massage of the affected dug follows bottom-up. Considering the severity of inflammatory process, the preparation is introduced in a dose 10 ml once a day (preferentially, after afternoon milking) every 24 hours to ensure complete recovery of the affected dug portion. (2-4 times).

EFFECT: improved therapeutic effectiveness.

9 tbl, 5 ex

FIELD: agriculture; veterinary science.

SUBSTANCE: application of cysteamine, its salt or composition, containing cysteamine or its salt, stabilizer and/or coated carrier to improve lactation of the milking animals, particularly cows.

EFFECT: increases milk yield, its fat and protein content.

42 cl, 24 tbl, 1 dwg

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to compounds of the general formula (I): wherein R1 represents (C1-C4)-alkyl with branched or linear chain; R2 represents hydrogen atom (H); R3 represents (C1-C4)-alkyl with branched or linear chain; R4 represents (C1-C4)-alkyl with branched or linear chain, (C2-C4)-alkenyl; R5 represents -SO2NR10R11; R8 represents (C1-C4)-alkyl with branched or linear chain; each R10 and R11 represents independently H or (C1-C12)-alkyl with branched or linear chain; or R10 and R11 in common with nitrogen atom to which they are bound form pyrrolinone group, piperidyl, morpholinyl, 4-N(R13)-piperazinyl that are substituted optionally with (C1-C4)-alkyl with branched or linear chain, -NR14R15, phenyl group substituted optionally with -OH or phenyl group bound in common with other substituted phenyl group by carbonyl group; R13 represents (C1-C4)-alkyl with branched or linear chain, (C2-C6)-alkyl with branched or linear chain and substituted with hydroxyl; (C2-C6)-alkyl with branched or linear chain substituted with phenyl; (C2-C6)-hydrocarbon with branched or linear chain substituted with -CO2R8; wherein each radical among R14 and R15 represents independently H; (C1-C4)-alkyl with branched or linear chain, or its pharmaceutically acceptable salt. The claimed compounds possess inhibitory effect on activity of phosphodiesterase-5 and can be used for production of drug for treatment or prophylaxis of diseases associated with phospholipase and its function. Also, invention relates to pharmaceutical composition, medicinal composition for veterinary science, and intermediate compounds IA-IG used for synthesis of compound of the formula (I).

EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

8 cl, 2 tbl, 4 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day.

EFFECT: method provides the 100% clinical effectiveness in latent mastitis, being less labour-consuming and environmentally safe as compared to the other methods.

Up!